What they say?
A recent study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ) by Prof Dominic J. Withers, Dr. Selman C and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports, for the first time, that: Life-extension therapy: MiRNA-1827 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span
Research findings to Therapeutic opportunity:
This study suggests an miRNA-based life extension therapy. MiR-1827, by decreasing the expression of its target gene, it may suppress Ribosomal protein S6 kinase 1 (p70S6 Kinase) expression. Thereby, it may promote: (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity (figs. 1 and 2).
Thus, pharmacological formulations encompassing “MiRNA-1827 or its activators or MiRNA-1827 in combination with any of the known longevity-promoting compound(s)“ can be used to extend the lifespan of an individual (fig. 2).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed Information: How MiR-1827 decreases the expression of p70 S6 Kinase and promotes mammalian life span?
# Research cooperation
Amount: $100 #
Citation: Boominathan, L., Life-extension therapy: MiRNA-1827 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 15/December/2016, 10.57 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org